Literature DB >> 1730093

Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells.

M Pettersson1, H Jernberg-Wiklund, L G Larsson, C Sundström, I Givol, Y Tsujimoto, K Nilsson.   

Abstract

The bcl-2 gene, encoding a mitochondrial membrane protein suggested to play an important role in cell survival, is translocated into the Ig loci in about 80% of human follicular lymphomas, which results in a high level of expression. This report shows that bcl-2 was expressed in eight of eight human multiple myeloma cell lines and in normal lymph node and bone marrow plasma cells. In the majority of the myeloma lines, the level of expression was comparable with that observed in Karpas 422, a follicular lymphoma cell line carrying a 14;18 translocation of the bcl-2 gene. DNA rearrangements of the bcl-2 locus were evident in only one of the myeloma cell lines, U-266-1970. In this cell line, which exhibited the highest bcl-2 expression, a fourfold increased copy number of the bcl-2 gene was estimated by Southern analysis. This amplification was lost in cells of later passages (U-266-1984), suggesting that bcl-2 might possibly have played a role in the tumor development in vivo. Our results are in contrast to previous observations in murine plasmacytoma, in which bcl-2 was shown to be silent. The results also contradict the published observation that bcl-2 is not expressed at terminal stages of B-cell differentiation. It is at present unclear whether the high expression of bcl-2 in human myeloma is the result of a deregulated expression associated with the malignant phenotype or a mere reflection of the bcl-2 expression typical of normal plasma cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730093

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2.

Authors:  H M Ogmundsdóttir; S Sveinsdóttir; A Sigfússon; I Skaftadóttir; J G Jónasson; B A Agnarsson
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

2.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

3.  Characterization and fed-batch culture of hybridoma overexpressing apoptosis suppressing gene bcl-2.

Authors:  S Terada; Y Itoh; H Ueda; E Suzuki
Journal:  Cytotechnology       Date:  1997-07       Impact factor: 2.058

4.  Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells.

Authors:  Tadi Satish Kumar; Vijayalakshmi Kari; Bibha Choudhary; Mridula Nambiar; T S Akila; Sathees C Raghavan
Journal:  J Biol Chem       Date:  2010-08-10       Impact factor: 5.157

Review 5.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

6.  CD4+ T cells downregulate Bcl-2 in germinal centers.

Authors:  André Almeida Schenka; Sabina Müller; Jean-Jacques Fournié; Florence Capila; José Vassallo; Georges Delsol; Salvatore Valitutti; Pierre Brousset
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

Review 7.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

Review 8.  Molecular pathology of low grade malignant lymphomas.

Authors:  H Ratech
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 9.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

10.  8-Chloroadenosine 3',5'-monophosphate induces cell cycle arrest and apoptosis in multiple myeloma cells through multiple mechanisms.

Authors:  Yi-Min Cheng; Qi Zhu; Yi-Yun Yao; Yong Tang; Ming-Ming Wang; Li-Fang Zou
Journal:  Oncol Lett       Date:  2012-09-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.